
    
      In the present study, the investigators will assess the efficacy and safety of the
      formulation of Omija extract(1,200 mg administered twice a day) on the symptoms of knee
      osteoarthritis (KO) during a 12-week treatment course. In a randomized, double-blind
      placebo-controlled trial, subjects will be randomly assign to receive oral omija treatment
      group(n=30) or placebo group(n=30). The primary efficacy outcome measure will be score change
      in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) after 12-weeks.
      Secondary parameters will be included the Lysholm index score, hs-CRP, osteocalcin(OSC), and
      deoxypyridinoline(DPYR).
    
  